Conditioned anti-immobility by ketamine: A comparison to escitalopram and bupropion.
Journal
Experimental and clinical psychopharmacology
ISSN: 1936-2293
Titre abrégé: Exp Clin Psychopharmacol
Pays: United States
ID NLM: 9419066
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
pubmed:
26
4
2022
medline:
23
3
2023
entrez:
25
4
2022
Statut:
ppublish
Résumé
This study was designed to explore the clinical belief that "set and setting" play an important role in favorable responses to psychedelic agents such as ketamine (KET). In fact, there is evidence in animals that the antidepressant effect of this drug may involve drug-environment interactions in which a context paired with its effects acquires the ability to influence behavior. Therefore, it was investigated in male Sprague-Dawley rats whether exposure to a context paired with the effects of KET, or with the effects of the common antidepressant medications bupropion (BUP) and escitalopram (ESC), could produce an antidepressant-like conditioned response. In Experiment 1, subjects received saline in a vehicle-paired context (denoted as CS-), and 0, 10, or 20 mg/kg KET, 10 mg/kg ESC, or 10 mg/kg BUP in a drug-paired context (denoted as CS +), on 10 alternating days (5 pairings with each context). The rats were then exposed drug free to the CS- and CS + prior to the assessment of immobility in the forced-swimming test. Experiment 2 assessed approach/avoidance responses induced by the CS- and CS + in a place-conditioning test. It was found that exposure to the KET CS + significantly reduced immobility without affecting general locomotor activity in comparison to the SAL CS + and the BUP CS +, but not the ESC CS+. Moreover, no group differences were observed in the place-conditioning test, indicating that the anti-immobility effect of the KET CS + was likely not influenced by a conditioned incentive or aversive state. Together, these data suggest that a KET-paired context can elicit a conditioned antidepressant-like response, which may be a mechanism involved in its sustained antidepressant clinical action. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Identifiants
pubmed: 35467924
pii: 2022-55826-001
doi: 10.1037/pha0000573
doi:
Substances chimiques
Ketamine
690G0D6V8H
Bupropion
01ZG3TPX31
Escitalopram
4O4S742ANY
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-361Subventions
Organisme : Ontario Brain Institute